|
Real-time Estimate
Cboe BZX
09:31:06 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 4.015 USD | -0.86% |
|
+10.66% | -0.98% |
Company Valuation: Recursion Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,895 | 1,461 | 2,136 | 2,666 | 2,129 | 2,421 | - | - |
| Change | - | -49.51% | 46.15% | 24.83% | -20.16% | 13.74% | - | - |
| Enterprise Value (EV) 1 | 2,379 | 918.1 | 1,745 | 2,099 | 1,404 | 1,968 | 2,062 | 2,360 |
| Change | - | -61.41% | 90.11% | 20.27% | -33.12% | 40.16% | 4.78% | 14.45% |
| P/E | -11.5x | -5.67x | -6.24x | -4x | -2.84x | -4.57x | -4.66x | -4.82x |
| PBR | 5.37x | 2.79x | 4.97x | 2.59x | 1.91x | 2.86x | 4.48x | 9.2x |
| PEG | - | 0.65x | -0.4x | -0.57x | 0.2x | 0.1x | 2.34x | 1.45x |
| Capitalization / Revenue | 284x | 36.7x | 47.9x | 45.3x | 28.5x | 57.9x | 45.7x | 19.2x |
| EV / Revenue | 234x | 23x | 39.2x | 35.7x | 18.8x | 47.1x | 38.9x | 18.7x |
| EV / EBITDA | -13.6x | -3.92x | -5.36x | -4.74x | -2.49x | -4.09x | -4.53x | -6.46x |
| EV / EBIT | -13x | -3.74x | -4.99x | -4.38x | -2.17x | -3.8x | -3.99x | -5.9x |
| EV / FCF | -12x | -7.61x | -5.82x | -5.63x | -3.71x | -9.46x | -10.6x | 15.7x |
| FCF Yield | -8.34% | -13.1% | -17.2% | -17.8% | -26.9% | -10.6% | -9.46% | 6.36% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.49 | -1.36 | -1.58 | -1.69 | -1.44 | -0.8865 | -0.8689 | -0.84 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.18 | 39.84 | 44.58 | 58.84 | 74.68 | 41.78 | 53.03 | 126.3 |
| EBITDA 1 | -174.4 | -234 | -325.7 | -442.5 | -564.4 | -481.1 | -455.5 | -365.6 |
| EBIT 1 | -182.8 | -245.7 | -350.1 | -479 | -648.1 | -518 | -517.4 | -400.1 |
| Net income 1 | -186.5 | -239.5 | -328.1 | -463.7 | -644.8 | -466.4 | -505.6 | -451.3 |
| Net Debt 1 | -515.8 | -543.3 | -390.4 | -566.9 | -724.6 | -453.3 | -359.1 | -61.23 |
| Reference price 2 | 17.130 | 7.710 | 9.860 | 6.760 | 4.090 | 4.050 | 4.050 | 4.050 |
| Nbr of stocks (in thousands) | 168,993 | 189,556 | 216,623 | 394,418 | 520,457 | 597,811 | - | - |
| Announcement Date | 3/23/22 | 2/27/23 | 2/27/24 | 2/28/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.57x | 47.1x | -4.09x | -.--% | 2.42B | |
| 17.08x | 6.33x | 12.4x | 1.75% | 63.48B | |
| 30.03x | 7.96x | 26.08x | 0.05% | 54.55B | |
| 37.03x | 6.57x | 19.63x | 0.87% | 53.59B | |
| 35.05x | 3.37x | 14.55x | -.--% | 44.75B | |
| 48.28x | 5.55x | 30.42x | -.--% | 41.62B | |
| -19.33x | 186.93x | -20.57x | -.--% | 39.91B | |
| 30.28x | 7.94x | 20.6x | 0.4% | 32.47B | |
| 36.51x | 6.64x | 22.27x | -.--% | 26.7B | |
| 26.96x | 5.67x | 14.71x | -.--% | 23.36B | |
| Average | 23.73x | 28.41x | 13.60x | 0.31% | 38.29B | |
| Weighted average by Cap. | 26.35x | 25.37x | 15.55x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RXRX Stock
- Valuation Recursion Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
